Key result
Recombinant human BNP linked to ~13% lower mean systemic filling pressure in post-cardiotomy heart failure.
Why the study?
Recombinant human brain natriuretic peptide is commonly used for decongestion, but its instant effects on cardiac output and venous return function in post-cardiotomy patients with CHF remained to be investigated.
Does recombinant human brain natriuretic peptide improve cardiac output and venous return function in post-cardiotomy patients with congestive heart failure?
Observational (n=24)
No
Does recombinant human brain natriuretic peptide improve cardiac output and venous return function in post-cardiotomy patients with congestive heart failure?
In post-cardiotomy heart failure patients, rh-BNP administration acutely improves venous return function and reduces cardiac congestion without significantly altering cardiac output.
Answers are grounded in this paper and cite their sources.
May reduce venous congestion post-cardiotomy; hypothesis-generating for RCTs on outcomes.
Aims Recombinant human brain natriuretic peptide (rh-BNP) is commonly used as a decongestive therapy. This study aimed to investigate the instant effects of rh-BNP on cardiac output and venous return function in post-cardiotomy patients with congestive heart failure (CHF). Methods and results Twenty-four post-cardiotomy heart failure patients were enrolled and received a standard loading dose of rh-BNP. Haemodynamic monitoring was performed via a pulmonary artery catheter before and after the administration of rh-BNP. The cardiac output and venous return functions were estimated by depicting Frank-Starling and Guyton curves. After rh-BNP infusion, variables reflecting cardiac congestion and venous return function, such as pulmonary artery wedge pressure, mean systemic filling pressure (Pmsf) and venous return resistance index (VRRI), reduced from 15 ± 3 to 13 ± 3 mmHg, from 32 ± 7 to 28 ± 7 mmHg and from 6.7 ± 2.6 to 5.7 ± 1.8 mmHg min m2/L, respectively. Meanwhile, cardiac index, stroke volume index, and the cardiac output function curve remained unchanged per se. The decline in Pmsf [−13% (−22% to −8%)] and VRRI [−12% (−25% to −5%)] was much greater than that in the systemic vascular resistance index [−7% (−14% to 0%)]. In the subgroup analysis of reduced ejection fraction (<40%) patients, the aforementioned changes were more significant. Conclusions rh-BNP might ameliorate venous return rather than cardiac output function in post-cardiotomy CHF patients.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2022) conducted an observational in post-cardiotomy congestive heart failure (n=24). Recombinant human brain natriuretic peptide (rh-BNP) vs. Baseline was evaluated on Mean systemic filling pressure (Pmsf) (p=0.002). Recombinant human brain natriuretic peptide significantly reduced mean systemic filling pressure from 32 to 28 mmHg and venous return resistance index in post-cardiotomy heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: